TG Therapeutics (NASDAQ:TGTX) Announces Earnings Results

TG Therapeutics (NASDAQ:TGTX) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02), Briefing.com reports. The company had revenue of $63.47 million during the quarter, compared to analyst estimates of $54.60 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. The company’s quarterly revenue was up 713.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.28) EPS.

TG Therapeutics Stock Performance

Shares of TGTX traded up $0.12 during mid-day trading on Thursday, hitting $16.00. 3,774,289 shares of the company’s stock were exchanged, compared to its average volume of 4,276,287. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of 800.40 and a beta of 2.33. The stock’s 50-day simple moving average is $15.13 and its 200-day simple moving average is $14.33. TG Therapeutics has a 52 week low of $6.46 and a 52 week high of $35.67.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TGTX. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $25.00 price objective on shares of TG Therapeutics in a report on Thursday, April 18th. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Thursday, February 29th. LADENBURG THALM/SH SH increased their price target on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of TG Therapeutics in a report on Thursday, April 18th. Finally, StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 24th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and an average price target of $29.17.

Insider Buying and Selling

In related news, Director Laurence N. Charney sold 22,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the sale, the director now owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.20% of the stock is currently owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.